Cargando…
A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib
INTRODUCTION: We report a case of renal cell carcinoma with vena cava thrombus showing a marked reduction with presurgical avelumab plus axitinib, facilitating nephrectomy with thrombectomy. CASE PRESENTATION: A 50‐year‐old man was taken to emergent care unit due to spontaneous renal rupture and was...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560442/ https://www.ncbi.nlm.nih.gov/pubmed/34755071 http://dx.doi.org/10.1002/iju5.12362 |
_version_ | 1784592933986500608 |
---|---|
author | Suzuki, Issei Kijima, Toshiki Takada‐Owada, Atsuko Nakamura, Gaku Uematsu, Toshitaka Sakamoto, Kazumasa Nishihara, Daisaku Ishida, Kazuyuki Kamai, Takao |
author_facet | Suzuki, Issei Kijima, Toshiki Takada‐Owada, Atsuko Nakamura, Gaku Uematsu, Toshitaka Sakamoto, Kazumasa Nishihara, Daisaku Ishida, Kazuyuki Kamai, Takao |
author_sort | Suzuki, Issei |
collection | PubMed |
description | INTRODUCTION: We report a case of renal cell carcinoma with vena cava thrombus showing a marked reduction with presurgical avelumab plus axitinib, facilitating nephrectomy with thrombectomy. CASE PRESENTATION: A 50‐year‐old man was taken to emergent care unit due to spontaneous renal rupture and was diagnosed to have left‐sided renal cell carcinoma with level IV tumor thrombus. After hemostasis was obtained via transcatheter arterial embolization, avelumab plus axitinib was introduced because upfront surgery was deemed unfeasible due to poor performance status and possible retroperitoneal tumor dissemination. After four treatment cycles, thrombus was reduced to level II, and nephrectomy with thrombectomy was performed. Histological analyses revealed massive CD8(+) T cell infiltration in the thrombus, suggesting immunotherapy efficacy. He has remained recurrence‐free without any additional treatment for eight months. CONCLUSION: For locally advanced renal cell carcinoma with vena cava thrombus, presurgical combination therapy with avelumab plus axitinib could be an option to facilitate curative surgery. |
format | Online Article Text |
id | pubmed-8560442 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85604422021-11-08 A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib Suzuki, Issei Kijima, Toshiki Takada‐Owada, Atsuko Nakamura, Gaku Uematsu, Toshitaka Sakamoto, Kazumasa Nishihara, Daisaku Ishida, Kazuyuki Kamai, Takao IJU Case Rep Case Reports INTRODUCTION: We report a case of renal cell carcinoma with vena cava thrombus showing a marked reduction with presurgical avelumab plus axitinib, facilitating nephrectomy with thrombectomy. CASE PRESENTATION: A 50‐year‐old man was taken to emergent care unit due to spontaneous renal rupture and was diagnosed to have left‐sided renal cell carcinoma with level IV tumor thrombus. After hemostasis was obtained via transcatheter arterial embolization, avelumab plus axitinib was introduced because upfront surgery was deemed unfeasible due to poor performance status and possible retroperitoneal tumor dissemination. After four treatment cycles, thrombus was reduced to level II, and nephrectomy with thrombectomy was performed. Histological analyses revealed massive CD8(+) T cell infiltration in the thrombus, suggesting immunotherapy efficacy. He has remained recurrence‐free without any additional treatment for eight months. CONCLUSION: For locally advanced renal cell carcinoma with vena cava thrombus, presurgical combination therapy with avelumab plus axitinib could be an option to facilitate curative surgery. John Wiley and Sons Inc. 2021-08-24 /pmc/articles/PMC8560442/ /pubmed/34755071 http://dx.doi.org/10.1002/iju5.12362 Text en © 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Case Reports Suzuki, Issei Kijima, Toshiki Takada‐Owada, Atsuko Nakamura, Gaku Uematsu, Toshitaka Sakamoto, Kazumasa Nishihara, Daisaku Ishida, Kazuyuki Kamai, Takao A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib |
title | A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib |
title_full | A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib |
title_fullStr | A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib |
title_full_unstemmed | A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib |
title_short | A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib |
title_sort | case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560442/ https://www.ncbi.nlm.nih.gov/pubmed/34755071 http://dx.doi.org/10.1002/iju5.12362 |
work_keys_str_mv | AT suzukiissei acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib AT kijimatoshiki acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib AT takadaowadaatsuko acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib AT nakamuragaku acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib AT uematsutoshitaka acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib AT sakamotokazumasa acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib AT nishiharadaisaku acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib AT ishidakazuyuki acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib AT kamaitakao acaseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib AT suzukiissei caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib AT kijimatoshiki caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib AT takadaowadaatsuko caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib AT nakamuragaku caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib AT uematsutoshitaka caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib AT sakamotokazumasa caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib AT nishiharadaisaku caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib AT ishidakazuyuki caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib AT kamaitakao caseofclearcellrenalcellcarcinomawithvenacavathrombusrespondingtopresurgicalavelumabandaxitinib |